ABI1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the widely used HeLa cervical adenocarcinoma cell line. This polyclonal format provides a genetically heterogeneous pool of cells harboring targeted disruptions in the ABI1 gene, enabling robust loss-of-function studies without the clonal variability inherent in single-cell-derived lines. The product serves as a versatile tool for investigating actin cytoskeleton dynamics, cell migration, and signal transduction pathways involving the scaffold protein ABI1. Researchers can employ these cells to dissect the molecular mechanisms by which ABI1 coordinates actin remodeling in both normal and pathological contexts.
HeLa cells, originally isolated from a cervical adenocarcinoma of a 31-year-old African American woman, are a well-established epithelial model in cancer biology. They are HPV-18 positive and exhibit transformed characteristics, including rapid proliferation and invasive potential, making them particularly suitable for studying oncogenic signaling and metastatic behavior. The epithelial origin of HeLa cells provides a relevant context for examining ABI1 function, as ABI1 is known to regulate cell adhesion and migration in carcinoma cells. This host cell background allows direct correlation of ABI1 knockout phenotypes with established HeLa cell biology and facilitates integration into existing experimental workflows.
ABI1 functions as an essential scaffold protein and core component of the WAVE regulatory complex (WRC), which also includes NCKAP1, CYFIP1, WASF2 (WAVE2), and BRK1. Mechanistically, ABI1 integrates upstream signals from activated receptor tyrosine kinases (such as EGFR and PDGFR) and the small GTPase Rac1, promoting assembly and activation of the WRC. In turn, the WRC stimulates the Arp2/3 complex to nucleate branched actin filaments, driving lamellipodial protrusion and cell migration. ABI1 also serves as an adaptor for Abl family kinases, receiving phosphorylation that modulates its activity and interactions. Disruption of ABI1 therefore impairs the linkage between growth factor or Rac1 signaling and the actin polymerization machinery, leading to defects in cytoskeletal reorganization, cell motility, and adhesion.
In the HeLa cervical carcinoma model, knockout of ABI1 is particularly significant for cancer research, as ABI1 overexpression has been associated with enhanced metastatic potential in solid tumors. Loss of ABI1 function can attenuate the migratory and invasive capacities of these cells, offering a system to study the molecular determinants of metastasis. Additionally, ABI1 is implicated in leukemogenesis through the MLL-ABI1 fusion protein found in acute myeloid leukemia, highlighting its role in aberrant actin remodeling and oncogenic transformation. By eliminating ABI1 expression in a well-characterized cancer cell line, this model enables dissection of ABI1-dependent pathways that contribute to tumor progression and provides a platform for evaluating therapeutic interventions.
These polyclonal knockout cells are ideally suited for a range of functional assays, including wound healing and Transwell migration/invasion assays to quantify cell motility, phalloidin staining to visualize F-actin structures, and co-immunoprecipitation to monitor WAVE complex integrity. Live-cell imaging of lamellipodia dynamics and Rho GTPase activation assays can further elucidate ABI1-mediated regulation of actin remodeling. Moreover, the cells can be used in drug screening campaigns to identify compounds that target actin cytoskeleton reorganization or inhibit metastatic behavior. For additional information or technical support regarding this product, please contact Ascent Research.
